Janux Therapeutics (JANX) Competitors $24.77 -0.63 (-2.48%) Closing price 04:00 PM EasternExtended Trading$24.77 0.00 (0.00%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JANX vs. LEGN, TGTX, TLX, VRNA, LNTH, AXSM, GRFS, NUVL, ADMA, and PCVXShould you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include Legend Biotech (LEGN), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Verona Pharma (VRNA), Lantheus (LNTH), Axsome Therapeutics (AXSM), Grifols (GRFS), Nuvalent (NUVL), ADMA Biologics (ADMA), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. Janux Therapeutics vs. Legend Biotech TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Verona Pharma Lantheus Axsome Therapeutics Grifols Nuvalent ADMA Biologics Vaxcyte Janux Therapeutics (NASDAQ:JANX) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, earnings, profitability, institutional ownership, media sentiment, valuation and risk. Which has preferable earnings & valuation, JANX or LEGN? Janux Therapeutics has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanux Therapeutics$9.34M157.00-$58.29M-$1.36-18.21Legend Biotech$728.30M7.14-$518.25M-$0.59-48.02 Does the media refer more to JANX or LEGN? In the previous week, Legend Biotech had 16 more articles in the media than Janux Therapeutics. MarketBeat recorded 37 mentions for Legend Biotech and 21 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.43 beat Legend Biotech's score of 0.79 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 15 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 14 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of JANX or LEGN? 75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 29.4% of Janux Therapeutics shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, JANX or LEGN? Janux Therapeutics has a beta of 3.24, suggesting that its share price is 224% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Is JANX or LEGN more profitable? Legend Biotech has a net margin of -66.92% compared to Janux Therapeutics' net margin of -463.91%. Janux Therapeutics' return on equity of -10.47% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Janux Therapeutics-463.91% -10.47% -9.86% Legend Biotech -66.92%-29.69%-19.45% Do analysts rate JANX or LEGN? Janux Therapeutics presently has a consensus target price of $95.25, indicating a potential upside of 284.54%. Legend Biotech has a consensus target price of $74.73, indicating a potential upside of 163.77%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Janux Therapeutics is more favorable than Legend Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.09Legend Biotech 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92 Does the MarketBeat Community favor JANX or LEGN? Legend Biotech received 48 more outperform votes than Janux Therapeutics when rated by MarketBeat users. Likewise, 73.02% of users gave Legend Biotech an outperform vote while only 70.97% of users gave Janux Therapeutics an outperform vote. CompanyUnderperformOutperformJanux TherapeuticsOutperform Votes4470.97% Underperform Votes1829.03% Legend BiotechOutperform Votes9273.02% Underperform Votes3426.98% SummaryJanux Therapeutics beats Legend Biotech on 12 of the 19 factors compared between the two stocks. Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JANX vs. The Competition Export to ExcelMetricJanux TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.47B$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-21.178.9226.8419.71Price / Sales157.00250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book3.326.466.794.50Net Income-$58.29M$143.98M$3.23B$248.18M7 Day Performance9.50%3.04%4.07%1.14%1 Month Performance-15.46%7.44%12.52%15.20%1 Year Performance-45.55%-2.46%16.83%6.56% Janux Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JANXJanux Therapeutics2.7762 of 5 stars$24.77-2.5%$95.25+284.5%-47.1%$1.47B$9.34M-21.1730Positive NewsLEGNLegend Biotech3.5386 of 5 stars$32.38+1.9%$78.82+143.4%-33.8%$5.95B$627.24M-34.081,070News CoverageAnalyst RevisionGap UpTGTXTG Therapeutics3.8254 of 5 stars$34.99+4.0%$40.80+16.6%+115.2%$5.56B$386.39M-349.87290Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.25-5.4%$22.00+35.4%N/A$5.49B$783.21M0.00N/AGap DownVRNAVerona Pharma2.6775 of 5 stars$67.53+6.6%$81.50+20.7%+484.7%$5.48B$118.54M-35.1730Positive NewsLNTHLantheus4.458 of 5 stars$79.52-2.7%$132.67+66.8%-7.3%$5.45B$1.54B13.23700Positive NewsHigh Trading VolumeAXSMAxsome Therapeutics4.7267 of 5 stars$110.16+2.2%$172.14+56.3%+39.7%$5.42B$432.16M-18.39380Positive NewsInsider TradeGRFSGrifols3.2195 of 5 stars$7.73+8.9%N/A+4.7%$5.31B$7.21B6.6126,300Positive NewsNUVLNuvalent2.6421 of 5 stars$73.63+5.4%$115.50+56.9%+7.0%$5.27BN/A-21.2240News CoveragePositive NewsADMAADMA Biologics3.1796 of 5 stars$20.45+2.4%$24.25+18.6%+117.2%$4.86B$459.38M73.04530News CoveragePositive NewsGap DownPCVXVaxcyte3.0977 of 5 stars$31.59+1.4%$136.50+332.1%-51.8%$4.08BN/A-6.87160News CoveragePositive NewsEarnings ReportGap Up Related Companies and Tools Related Companies LEGN Competitors TGTX Competitors TLX Competitors VRNA Competitors LNTH Competitors AXSM Competitors GRFS Competitors NUVL Competitors ADMA Competitors PCVX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JANX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy JANX Stock Free JANX Stock Alerts